Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of … Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.

    Synonyms: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
  2. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    , while Neulasta has a single 20 Kd PEG group attached at the N terminal end of the wild type G-CSF protein. … MAXY-G34 is pegylated with 5 kd mPEG SPA (succinimidyl propionate) groups at 3 amino acid residues, including PEG groups attached at the amino terminal end of the protein and at two internal lysine residues

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].

  4. Drug

    Benfotiamine

    go.drugbank.com/drugs/DB11748
    ApprovedInvestigationalWithdrawn

    Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Thioridazine

    go.drugbank.com/drugs/DB00679
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias. … A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity.

    Synonyms: 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine
  6. Drug

    Ammonia N-13

    go.drugbank.com/drugs/DB09326
    Approved

    Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. … Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease

    Synonyms: Ammonia N 13, Ammonia N-13Products: Ammonia N 13 N 13, Ammonia N 13
  7. Drug

    Avacincaptad pegol

    go.drugbank.com/drugs/DB15165
    ApprovedInvestigational

    Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. … It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA).

  8. Drug

    Esterified estrogens

    go.drugbank.com/drugs/DB09381
    Approved

    Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the

  9. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    New Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  10. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

    Synonyms: 2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1- methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-, N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamide